Beer, Lynn A.
Senapati, Suneeta
Sammel, Mary D.
Barnhart, Kurt T.
Schreiber, Courtney A.
Speicher, David W.
Funding for this research was provided by:
National Institutes of Health (RO1HD076279, RO1HD076279)
National Cancer Institute (CA10815)
Article History
Received: 16 December 2021
Accepted: 1 February 2022
First Online: 21 February 2022
Declarations
:
: This study was approved by the Institutional Review Boards of the Wistar Institute and the University of Pennsylvania and complied with the Declaration of Helsinki. Informed written consent was obtained from all participants.
: Not applicable.
: CAS has served as a consultant for Medicines360 and Myovant Pharmaceuticals. The Perelman School of Medicine, University of Pennsylvania Department of Obstetrics and Gynecology (CAS) has received research funding from Bayer Healthcare, Sebela, and Medicines360. No other disclosures were reported.